title: Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial.
abstract: OBJECTIVE
  This multinational, multicentre, prospective, randomised, double blind, parallel group, non-inferiority study compared the efficacy and safety of moxifloxacin monotherapy with ofloxacin plus metronidazole in women with uncomplicated pelvic inflammatory disease.
  
  
  METHODS
  Women from hospitals throughout 13 countries received a 14 day course of either oral moxifloxacin, 400 mg once daily (n = 384), or oral ofloxacin, 400 mg twice daily plus oral metronidazole, 500 mg twice daily (n = 365).
  
  
  RESULTS
  Of the 741 patients in the intent to treat (ITT) population, 564 (74.2%) were valid for the per protocol (PP) analyses; 112 (19.9%) of these were included in the microbiologically valid population (MBV). Clinical resolution rates in the PP population at the test of cure visit (TOC, 5-24 days post-therapy, primary efficacy end point) were 90.2% (248/275) for moxifloxacin and 90.7% (262/289) for ofloxacin plus metronidazole (95% CI: -5.7% to 4.0%). At follow up (28-42 days post-therapy), resolution rates in the PP population were 85.8% (236/275) and 87.9% (254/289) for moxifloxacin and comparator, respectively (95% CI: -8.0% to 3.1%). Bacteriological success rates in the MBV population at TOC were 87.5% (49/56) for moxifloxacin and 82.1% (46/56) for comparator (95% CI: -8.3% to 18.8%). Against Chlamydia trachomatis and Neisseria gonorrhoeae, bacteriological success rates with moxifloxacin were 88.5% (23/26) and 100% (13/13) and for comparator 85.7% (18/21) and 81.8% (18/22), respectively. Drug related adverse events occurred less frequently with moxifloxacin (22.5% (85/378)) versus the comparator (30.9% (112/363)) (p = 0.01).
  
  
  CONCLUSIONS
  In uncomplicated PID, once daily moxifloxacin monotherapy was clinically and bacteriologically as efficacious as twice daily ofloxacin plus metronidazole therapy and was associated with fewer drug related adverse events.
authors.affiliation: Whittall Street Clinic, Whittall Street, Birmingham B4 6DH, UK. jonathan.ross@hobtpct.nhs.uk
authors.forename: J D C
authors.initials: JD
authors.lastname: Ross
authors.forename: H S
authors.initials: HS
authors.lastname: Cronjé
authors.forename: T
authors.initials: T
authors.lastname: Paszkowski
authors.forename: I
authors.initials: I
authors.lastname: Rakoczi
authors.forename: D
authors.initials: D
authors.lastname: Vildaite
authors.forename: A
authors.initials: A
authors.lastname: Kureishi
authors.forename: M
authors.initials: M
authors.lastname: Alefelder
authors.forename: P
authors.initials: P
authors.lastname: Arvis
authors.forename: P
authors.initials: P
authors.lastname: Reimnitz
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D001372:Aza Compounds / Q000008:administration & dosage*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008795:Metronidazole / Q000008:administration & dosage*; D000077266:Moxifloxacin; D015242:Ofloxacin / Q000008:administration & dosage*; D010146:Pain / Q000209:etiology; D010147:Pain Measurement; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy*; D011446:Prospective Studies; D011804:Quinolines / Q000008:administration & dosage*
chemical_list: D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D008795:Metronidazole; D015242:Ofloxacin; D000077266:Moxifloxacin